Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in incompletely resected or recurrent ependymoma
NCT04408092Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Jun 2013
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of sargramostim in ependymoma (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Number of participants with increased M/M infiltration compared to institutional and ACNS0121 controls at 8 years. Started Jun 2013; status: completed.
02
Drugs
sargramostim
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT04408092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408092.